These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32945468)

  • 1. A novel HDAC1 inhibitor, CBUD‑1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
    Kim SL; La MT; Shin MW; Kim SW; Kim HK
    Int J Oncol; 2020 Oct; 57(4):1027-1038. PubMed ID: 32945468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation.
    Lee HY; Tang DW; Liu CY; Cho EC
    Chem Biol Interact; 2022 Jan; 352():109778. PubMed ID: 34929181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin.
    Wang LT; Liou JP; Li YH; Liu YM; Pan SL; Teng CM
    Oncotarget; 2014 Jul; 5(14):5651-62. PubMed ID: 25015091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
    Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
    Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
    Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
    Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
    Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
    Zhijun H; Shusheng W; Han M; Jianping L; Li-Sen Q; Dechun L
    Tumour Biol; 2016 Aug; 37(8):10257-67. PubMed ID: 26831668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, characterization, and evaluation of Cd[L-proline]
    Chidambaram A; Sekar A; S H K; Chidambaram RK; Arunachalam K; G P S; Vilwanathan R
    Invest New Drugs; 2017 Dec; 35(6):691-705. PubMed ID: 28776290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
    Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
    Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo.
    Chen CH; Lee CH; Liou JP; Teng CM; Pan SL
    Oncotarget; 2015 Nov; 6(34):35991-6002. PubMed ID: 26462017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
    Flis S; Gnyszka A; Flis K; Spławiński J
    Eur J Pharmacol; 2010 Feb; 627(1-3):26-32. PubMed ID: 19853597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
    Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells.
    Tsai FL; Huang HL; Lai MJ; Liou JP; Pan SL; Yang CR
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the E2F1/Rb/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth.
    Duan N; Hu X; Qiu H; Zhou R; Li Y; Lu W; Zhu Y; Shen S; Wu W; Yang F; Liu N
    Cell Death Dis; 2023 Dec; 14(12):801. PubMed ID: 38062013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
    Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
    Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
    Flis S; Gnyszka A; Spławiński J
    Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HDAC1 Inhibitor CBUD-1001 Enhances TRAIL-induced Apoptosis in Colorectal Cancer Cells.
    Shin MW; Kim SL; Yang HC; Yim SK; Seo SY; Lee ST; Kim HK; Kim SW
    Anticancer Res; 2021 Sep; 41(9):4353-4364. PubMed ID: 34475055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
    Singh A; Chang TY; Kaur N; Hsu KC; Yen Y; Lin TE; Lai MJ; Lee SB; Liou JP
    Eur J Med Chem; 2021 Apr; 215():113169. PubMed ID: 33588178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.